RedHill Biopharma (RDHL) Consolidated Net Income: 2012-2023
Historic Consolidated Net Income for RedHill Biopharma (RDHL) over the last 11 years, with Jun 2023 value amounting to $58.9 million.
- RedHill Biopharma's Consolidated Net Income rose 231.03% to $58.9 million in Q2 2023 from the same period last year, while for Jun 2023 it was -$40.0 million, marking a year-over-year increase of 75.62%. This contributed to the annual value of -$8.3 million for FY2024, which is 134.57% down from last year.
- Latest data reveals that RedHill Biopharma reported Consolidated Net Income of $58.9 million as of Q2 2023, which was up 844.05% from -$7.9 million recorded in Q1 2023.
- In the past 5 years, RedHill Biopharma's Consolidated Net Income registered a high of $58.9 million during Q2 2023, and its lowest value of -$145.2 million during Q4 2021.
- Its 3-year average for Consolidated Net Income is -$17.0 million, with a median of $2.4 million in 2022.
- Per our database at Business Quant, RedHill Biopharma's Consolidated Net Income soared by 232.46% in 2020 and then crashed by 469.08% in 2021.
- RedHill Biopharma's Consolidated Net Income (Quarterly) stood at $11.8 million in 2019, then skyrocketed by 232.46% to $39.4 million in 2020, then tumbled by 469.08% to -$145.2 million in 2021, then skyrocketed by 52.14% to -$69.5 million in 2022, then skyrocketed by 231.03% to $58.9 million in 2023.
- Its Consolidated Net Income stands at $58.9 million for Q2 2023, versus -$7.9 million for Q1 2023 and -$69.5 million for Q4 2022.